HighTower Advisors’s Sarepta Therapeutics SRPT Stock Holding History

HighTower Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-500	Closed	-$8	–	4045
2025 Q2	$8	Hold	500	–	–	﹤0.01%	3752
2025 Q1	$1.44K	Buy	+500	New	+$52.6K	﹤0.01%	3640
2020 Q4	–	Sell	-200	Closed	-$2K	–	2797
2020 Q3	$2K	Hold	200	–	–	﹤0.01%	2509
2020 Q2	$2K	Sell	200 -100	-33%	-$13.6K	﹤0.01%	2387
2020 Q1	$6K	Sell	300 -300	-50%	-$34.3K	﹤0.01%	2140
2019 Q4	$10K	Sell	600 -300	-33%	-$30.3K	﹤0.01%	2202
2019 Q3	$2K	Buy	900 +700	+350%	+$82.7K	﹤0.01%	2372
2019 Q2	$5K	Hold	200	–	–	﹤0.01%	2322
2019 Q1	$1K	Buy	+200	New	+$25.7K	﹤0.01%	2285
2018 Q3	–	Sell	-100	Closed	-$1K	–	2412
2018 Q2	$1K	Buy	+100	New	+$9.43K	﹤0.01%	2224
2017 Q4	–	Sell	-200	Closed	-$2K	–	2374
2017 Q3	$2K	Buy	+200	New	+$7.99K	﹤0.01%	2194
2017 Q2	–	Sell	-500	Closed	-$1K	–	2318
2017 Q1	$1K	Buy	+500	New	+$15.5K	﹤0.01%	2073

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors's SRPT Position: Q1 2026 in Review

HighTower Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 9,769 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #3439 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in SRPT as recently as Q3 2025.

HighTower Advisors first reported a position in SRPT in Q1 2016 and has held it in 40 quarters since. The position peaked at $7.86M in Q2 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

HighTower Advisors held 9,769 shares of Sarepta Therapeutics worth $213K as of Q1 2026.
Sarepta Therapeutics was a new HighTower Advisors position in Q1 2026.
Sarepta Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3439 holding.
HighTower Advisors first reported a position in Sarepta Therapeutics in Q1 2016 and has held it in 40 quarters since.
HighTower Advisors's Sarepta Therapeutics position peaked at $7.86M in Q2 2024.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.